Waters Completes Combination with BD Biosciences and Diagnostic Solutions Businesses

Waters Corporation (Milford, Massachusetts) has announced that it has completed its previously disclosed combination with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company (BD).¹ The transaction brings BD’s biosciences and diagnostics operations together with Waters’ existing analytical instrumentation, separations technologies, and software portfolio. According to Waters, the combination establishes a broader scientific and operational footprint spanning analytical chemistry, biological research, and diagnostic applications.¹

Following the transaction, Waters reported that the combined company is organized into four operating divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences.¹ The company stated that this divisional structure is intended to align technologies and workflows across a range of laboratory environments, including pharmaceutical development, biopharmaceutical manufacturing, clinical testing, and applied materials analysis. Waters emphasized that the organization would focus on high‑volume testing in regulated laboratory applications to expand its presence in high‑growth adjacent markets.

"Our combination with BD's Biosciences and Diagnostic Solutions businesses marks a pivotal moment for Waters, bringing together world-class scientific expertise across chemistry, physics, and biology, with rich histories of innovation," said Udit Batra, Ph.D., president and chief executive officer, Waters. "As we enter this next chapter, our focus is clear: address our customers' unmet needs, deliver long-term value for our shareholders, and provide solutions that advance global health. Through our category-defining products and shared culture of innovation, I am confident that together we will accelerate the benefits of pioneering science."

In addition to the organizational changes, Waters announced an update to its Board of Directors. Claire M. Fraser, Ph.D., was appointed to the board, increasing its size to eleven members. Fraser is a genome scientist with experience leading large research institutes and working across genomics, microbiology, infectious disease research, and molecular diagnostics, with her background aligning with the biosciences and diagnostics components of the combined organization. Fraser previously served as Director of The Institute for Genome Sciences at the University of Maryland School of Medicine and was also professor of medicine and microbiology and immunology at the university.

"As we reach this important milestone, I want to welcome our new colleagues to Waters and Dr. Claire Fraser to our Board," said Flemming Ørnskov, M.D., M.P.H., chairman, Waters. "We will benefit from her expertise and deep knowledge of the business to help oversee our next era of growth and value creation."

In the area of bioseparations, the combination brings together Waters’ strengths in analytical chemistry and separations with BD’s capabilities in biologics. The merger is expected to support the development of next‑generation consumables for large‑molecule analysis, enabling faster and more efficient workflows for biologic drug development.

The combination also has implications for bioanalytical characterization. Waters has emphasized progress toward creating a “laboratory of the future” for biologics, and the expanded organization will integrate techniques including flow cytometry, liquid chromatography–mass spectrometry (LC–MS), and light scattering.

Overall, the announcement confirms the formal completion of the combination and outlines the high‑level organizational and governance changes resulting from the transaction.¹

To read more on the merger, see our coverage here:

Waters Corporation Shareholders Approve Share Issuance for Planned Combination with BD Biosciences and Diagnostics

Waters to Merge with BD Biosciences in $17.5 Billion Life Sciences Deal

Reference

1. Waters Newsroom, Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses https://ir.waters.com/News--Events/newsroom/news-details/2026/Waters-Completes-Combination-with-BDs-Biosciences--Diagnostic-Solutions-Businesses/default.aspx (accessed 2026-02-10).